Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

RNA Interference01:23

RNA Interference

26.4K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.4K
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

118
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
118
Experimental RNAi02:15

Experimental RNAi

6.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.2K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

17.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.0K
Nonsense-mediated mRNA Decay02:27

Nonsense-mediated mRNA Decay

2.9K
2.9K
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.0K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Repurposing Non-oncologic Drugs via Targeted Nanocarriers for Cancer Therapy: Mechanisms, Synergistic Combinations, and Clinical Translation.

AAPS PharmSciTech·2026
Same author

A Phase-Resolved Geometric Deep Learning Framework Maps Structural Determinants of Disease-Associated Protein Aggregation and Guides Suppressor Design.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Nitro-substituted ruthenium(II) polypyridyl complexes synergise with ATR inhibitors to enhance replication stress in cancer cells.

Dalton transactions (Cambridge, England : 2003)·2026
Same author

Olaparib synergy screen reveals Exemestane induces replication stress in triple-negative breast cancer.

Molecular oncology·2025
Same author

Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies.

Medical oncology (Northwood, London, England)·2025
Same author

Integrated transcriptomic profiling reveals a STING-mediated Type II Interferon signature in SOD1-mutant amyotrophic lateral sclerosis models.

Communications biology·2025

Related Experiment Video

Updated: Sep 10, 2025

Delivery of the Cas9/sgRNA Ribonucleoprotein Complex in Immortalized and Primary Cells via Virus-like Particles "Nanoblades"
09:23

Delivery of the Cas9/sgRNA Ribonucleoprotein Complex in Immortalized and Primary Cells via Virus-like Particles "Nanoblades"

Published on: March 31, 2021

5.1K

Programmable self-replicating JEV nanotherapeutics redefine RNA delivery in ALS.

Yan Shan Loo1, Nur Aininie Yusoh2, Keyin Yap1

  • 1School of Science, Monash University Malaysia, Jalan Lagoon Selatan, Selangor, Malaysia.

Communications Biology
|August 26, 2025
PubMed
Summary

Engineered Japanese encephalitis virus (JEV) could deliver antisense oligonucleotides (ASO) to motor neurons for treating amyotrophic lateral sclerosis (ALS). This novel nanocarrier strategy aims for targeted, sustained gene therapy across the blood-brain barrier.

More Related Videos

DNA-Tethered RNA Polymerase for Programmable In vitro Transcription and Molecular Computation
09:26

DNA-Tethered RNA Polymerase for Programmable In vitro Transcription and Molecular Computation

Published on: December 29, 2021

4.3K
Engineering and Evolution of Synthetic Adeno-Associated Virus AAV Gene Therapy Vectors via DNA Family Shuffling
21:55

Engineering and Evolution of Synthetic Adeno-Associated Virus AAV Gene Therapy Vectors via DNA Family Shuffling

Published on: April 2, 2012

28.6K

Related Experiment Videos

Last Updated: Sep 10, 2025

Delivery of the Cas9/sgRNA Ribonucleoprotein Complex in Immortalized and Primary Cells via Virus-like Particles "Nanoblades"
09:23

Delivery of the Cas9/sgRNA Ribonucleoprotein Complex in Immortalized and Primary Cells via Virus-like Particles "Nanoblades"

Published on: March 31, 2021

5.1K
DNA-Tethered RNA Polymerase for Programmable In vitro Transcription and Molecular Computation
09:26

DNA-Tethered RNA Polymerase for Programmable In vitro Transcription and Molecular Computation

Published on: December 29, 2021

4.3K
Engineering and Evolution of Synthetic Adeno-Associated Virus AAV Gene Therapy Vectors via DNA Family Shuffling
21:55

Engineering and Evolution of Synthetic Adeno-Associated Virus AAV Gene Therapy Vectors via DNA Family Shuffling

Published on: April 2, 2012

28.6K

Area of Science:

  • Neuroscience
  • Virology
  • Gene Therapy

Background:

  • Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with limited treatment options.
  • Effective delivery of therapeutics to the central nervous system (CNS) is a major hurdle for ALS gene therapy.
  • Antisense oligonucleotides (ASO) and CRISPR/Cas9 show promise but require efficient delivery vectors.

Purpose of the Study:

  • To propose a novel strategy for targeted therapeutic delivery to motor neurons in the CNS.
  • To explore the use of engineered Japanese encephalitis virus (JEV) as a nanocarrier for ASO delivery.
  • To overcome the blood-brain and blood-spinal cord barriers (BBB/BSCB) for enhanced gene therapy in neurodegenerative diseases.

Main Methods:

  • Engineering Japanese encephalitis virus (JEV) to act as a self-replicating nanocarrier.
  • Incorporating antisense oligonucleotide (ASO) sequences into the JEV genome for co-packaging.
  • Utilizing JEV's natural neurotropism and immune cell-mediated entry for CNS targeting.
  • Employing microRNA (miRNA)-mediated attenuation for enhanced safety and CNS specificity.

Main Results:

  • The proposed JEV-based nanocarrier system theoretically enables targeted ASO delivery to motor neurons.
  • This approach leverages JEV's properties to bypass the BBB/BSCB, facilitating CNS penetration.
  • Co-packaging of ASO within the JEV genome allows for sustained therapeutic release.

Conclusions:

  • Engineered JEV presents a potential paradigm shift for CNS gene therapy in ALS and other neurodegenerative conditions.
  • This strategy offers a theoretical framework for efficient, targeted, and sustained ASO delivery.
  • Experimental validation is crucial to confirm the safety and therapeutic efficacy of this approach.